Royalty Pharma (RPRX) EPS (Basic) Growth (3y) (2023 - 2026)
Powered by 
Analysis
Royalty Pharma (RPRX) EPS (Basic) Growth (3y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 86.03% |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | 18.44% |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 37.21% |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 36.73% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -38.31% |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 67.51% |
| 10 | Incyte | 25.64 Bn | 21.11 Bn | 1.57 Bn | 47.44% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -38.31% |
| Mar 31, 2026 | -2.10% |
| Dec 31, 2025 | 37.41% |
| Sep 30, 2025 | 27.03% |
| Jun 30, 2025 | -42.10% |
| Mar 31, 2025 | 50.07% |
| Dec 31, 2024 | 79.31% |
| Sep 30, 2024 | 51.51% |
| Jun 30, 2024 | -39.75% |
| Mar 31, 2024 | -26.48% |
| Dec 31, 2023 | 17.97% |
| Sep 30, 2023 | -45.56% |
| Jun 30, 2023 | -22.88% |